Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
The latest announcement is out from Myriad Genetics (MYGN).
Myriad Genetics, Inc. and its current and former directors and officers faced shareholder derivative complaints alleging breaches of fiduciary duties. These complaints were consolidated and a settlement has been proposed, which includes corporate governance reforms and attorney fees capped at $950,000. The settlement awaits court approval, with a hearing scheduled for August 6, 2024.
See more insights into MYGN stock on TipRanks’ Stock Analysis page.
